Skip to main content
Top
Published in: BMC Primary Care 1/2018

Open Access 01-12-2018 | Research article

Factors related to intentional non-initiation of bisphosphonate treatment in patients with a high fracture risk in primary care: a qualitative study

Authors: Karin M. A. Swart, Myrthe van Vilsteren, Wesley van Hout, Esther Draak, Babette C. van der Zwaard, Henriette E. van der Horst, Jacqueline G. Hugtenburg, Petra J. M. Elders

Published in: BMC Primary Care | Issue 1/2018

Login to get access

Abstract

Background

Adherence to osteoporosis treatment is crucial for good treatment effects. However, adherence has been shown to be poor and a substantial part of the patients don’t even initiate treatment. This study aimed to gain insight into the considerations of both osteoporosis patients and general practitioners (GP) concerning intentional non-initiation of bisphosphonate treatment.

Methods

Osteoporosis patients and GPs were recruited from the SALT Osteoporosis Study and a transmural fracture liaison service, both carried out in the Netherlands. Using questionnaires, we identified non-starters and starters of bisphosphonate treatment. Semi-structured interviews were conducted to gain a detailed overview of all considerations until saturation of the data was reached. Starters were asked to reflect on the considerations that were brought forward by the non-starters. Interviews were open coded and the codes were classified into main themes and subthemes using an inductive approach.

Results

16 non-starters, 10 starters, and 13 GPs were interviewed. We identified three main themes: insufficient medical advice, attitudes towards medication use including concerns about side effects, and disease awareness. From patients’ as well as GPs’ perspective, insufficient or ambiguous information from the GP influenced the decision of the non-starters to not start bisphosphonates. In contrast, starters were either properly informed, or they collected information themselves. Patients’ aversion towards medication, fear of side effects, and a low risk perception also contributed to not starting the medication, whereas starters were aware of their fracture risk and were confident of the outcome of the treatment. Concerns about osteoporosis treatment and its side effects were also expressed by several GPs. Some GPs appeared to have a limited understanding of the current osteoporosis guidelines and the indications for treatment.

Conclusions

Many reasons we found for not starting bisphosphonate treatment were related to the patients or the GPs themselves being insufficiently informed. Attitudes of the GPs were shown to play a role in the decision of patients not to start treatment. Interventions need to be developed that are aimed at GPs, and at education of patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Poos M, Gommer A. Hoe vaak komt osteoporose voor en hoeveel mensen sterven eraan? RIVM: Bilthoven; 2009. Poos M, Gommer A. Hoe vaak komt osteoporose voor en hoeveel mensen sterven eraan? RIVM: Bilthoven; 2009.
2.
go back to reference Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8:136.CrossRefPubMedPubMedCentral Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8:136.CrossRefPubMedPubMedCentral
3.
go back to reference Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int. 2009;20:1633–50.CrossRefPubMed Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int. 2009;20:1633–50.CrossRefPubMed
4.
go back to reference Lotters FJ, van den Bergh JP, de Vries F, Rutten-van Molken MP. Current and future incidence and costs of osteoporosis-related fractures in the Netherlands: combining claims data with BMD measurements. Calcif Tissue Int. 2016;98:235–43.CrossRefPubMedPubMedCentral Lotters FJ, van den Bergh JP, de Vries F, Rutten-van Molken MP. Current and future incidence and costs of osteoporosis-related fractures in the Netherlands: combining claims data with BMD measurements. Calcif Tissue Int. 2016;98:235–43.CrossRefPubMedPubMedCentral
5.
go back to reference Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:570–8.CrossRefPubMed Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:570–8.CrossRefPubMed
6.
go back to reference Dursun N, Dursun E, Yalcin S. Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Int J Clin Pract. 2001;55:505–9.PubMed Dursun N, Dursun E, Yalcin S. Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Int J Clin Pract. 2001;55:505–9.PubMed
7.
go back to reference Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;1:CD001155. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;1:CD001155.
8.
go back to reference Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009;122(Suppl 2):3–13.CrossRef Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009;122(Suppl 2):3–13.CrossRef
9.
go back to reference Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14:571–81.CrossRefPubMed Ross S, Samuels E, Gairy K, Iqbal S, Badamgarav E, Siris E. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14:571–81.CrossRefPubMed
10.
go back to reference Sharman Moser S, Yu J, Goldshtein I, Ish-Shalom S, Rouach V, Shalev V, et al. Cost and consequences of nonadherence with oral bisphosphonate therapy: findings from a real-world data analysis. Ann Pharmacother. 2016;50:262–9.CrossRefPubMed Sharman Moser S, Yu J, Goldshtein I, Ish-Shalom S, Rouach V, Shalev V, et al. Cost and consequences of nonadherence with oral bisphosphonate therapy: findings from a real-world data analysis. Ann Pharmacother. 2016;50:262–9.CrossRefPubMed
11.
go back to reference Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691–705.CrossRefPubMedPubMedCentral Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73:691–705.CrossRefPubMedPubMedCentral
12.
go back to reference Hugtenburg JG, Timmers L, Elders PJ, Vervloet M, van Dijk L. Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions. Patient Prefer Adherence. 2013;7:675–82.CrossRefPubMedPubMedCentral Hugtenburg JG, Timmers L, Elders PJ, Vervloet M, van Dijk L. Definitions, variants, and causes of nonadherence with medication: a challenge for tailored interventions. Patient Prefer Adherence. 2013;7:675–82.CrossRefPubMedPubMedCentral
13.
go back to reference Reynolds K, Muntner P, Cheetham TC, Harrison TN, Morisky DE, Silverman S, et al. Primary non-adherence to bisphosphonates in an integrated healthcare setting. Osteoporos Int. 2013;24:2509–17.CrossRefPubMed Reynolds K, Muntner P, Cheetham TC, Harrison TN, Morisky DE, Silverman S, et al. Primary non-adherence to bisphosphonates in an integrated healthcare setting. Osteoporos Int. 2013;24:2509–17.CrossRefPubMed
15.
go back to reference Scoville EA, Ponce de Leon Lovaton P, Shah ND, Pencille LJ, Montori VM. Why do women reject bisphosphonates for osteoporosis? A videographic study. PLoS One. 2011;6:e18468.CrossRefPubMedPubMedCentral Scoville EA, Ponce de Leon Lovaton P, Shah ND, Pencille LJ, Montori VM. Why do women reject bisphosphonates for osteoporosis? A videographic study. PLoS One. 2011;6:e18468.CrossRefPubMedPubMedCentral
16.
go back to reference Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med. 2008;23:1815–21.CrossRefPubMedPubMedCentral Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med. 2008;23:1815–21.CrossRefPubMedPubMedCentral
17.
go back to reference Yu J, Brenneman SK, Sazonov V, Modi A. Reasons for not initiating osteoporosis therapy among a managed care population. Patient Prefer Adherence. 2015;9:821–30.PubMedPubMedCentral Yu J, Brenneman SK, Sazonov V, Modi A. Reasons for not initiating osteoporosis therapy among a managed care population. Patient Prefer Adherence. 2015;9:821–30.PubMedPubMedCentral
18.
go back to reference Sabaté E. Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization; 2003. Sabaté E. Adherence to long-term therapies. Evidence for action. Geneva: World Health Organization; 2003.
19.
go back to reference Charmaz K. Constructing Grounded Theory: A Practical Guide through Qualitative Analysis (1st ed.): SAGE Publications Ltd; 2006. Charmaz K. Constructing Grounded Theory: A Practical Guide through Qualitative Analysis (1st ed.): SAGE Publications Ltd; 2006.
20.
go back to reference Elders PJM, Merlijn T, Swart KMA, van Hout W, van der Zwaard BC, Niemeijer C, et al. Design of the SALT osteoporosis study: a randomised pragmatic trial, to study a primary care screening and treatment program for the prevention of fractures in women aged 65 years or older. BMC Musculoskelet Disord. 2017;18:424.CrossRefPubMedPubMedCentral Elders PJM, Merlijn T, Swart KMA, van Hout W, van der Zwaard BC, Niemeijer C, et al. Design of the SALT osteoporosis study: a randomised pragmatic trial, to study a primary care screening and treatment program for the prevention of fractures in women aged 65 years or older. BMC Musculoskelet Disord. 2017;18:424.CrossRefPubMedPubMedCentral
21.
go back to reference Sale JE, Beaton DE, Sujic R, Bogoch ER. ‘If it was osteoporosis, I would have really hurt myself.’ Ambiguity about osteoporosis and osteoporosis care despite a screening programme to educate fragility fracture patients. J Eval Clin Pract. 2010;16:590–6.PubMed Sale JE, Beaton DE, Sujic R, Bogoch ER. ‘If it was osteoporosis, I would have really hurt myself.’ Ambiguity about osteoporosis and osteoporosis care despite a screening programme to educate fragility fracture patients. J Eval Clin Pract. 2010;16:590–6.PubMed
22.
go back to reference Zeber JE, Manias E, Williams AF, Hutchins D, Udezi WA, Roberts CS, et al. A systematic literature review of psychosocial and behavioral factors associated with initial medication adherence: a report of the ISPOR medication adherence & persistence special interest group. Value Health. 2013;16:891–900.CrossRefPubMed Zeber JE, Manias E, Williams AF, Hutchins D, Udezi WA, Roberts CS, et al. A systematic literature review of psychosocial and behavioral factors associated with initial medication adherence: a report of the ISPOR medication adherence & persistence special interest group. Value Health. 2013;16:891–900.CrossRefPubMed
23.
go back to reference Schousboe JT. Adherence with medications used to treat osteoporosis: behavioral insights. Curr Osteoporos Rep. 2013;11:21–9.CrossRefPubMed Schousboe JT. Adherence with medications used to treat osteoporosis: behavioral insights. Curr Osteoporos Rep. 2013;11:21–9.CrossRefPubMed
24.
go back to reference Salter C, McDaid L, Bhattacharya D, Holland R, Marshall T, Howe A. Abandoned acid? Understanding adherence to bisphosphonate medications for the prevention of osteoporosis among older women: a qualitative longitudinal study. PLoS One. 2014;9:e83552.CrossRefPubMedPubMedCentral Salter C, McDaid L, Bhattacharya D, Holland R, Marshall T, Howe A. Abandoned acid? Understanding adherence to bisphosphonate medications for the prevention of osteoporosis among older women: a qualitative longitudinal study. PLoS One. 2014;9:e83552.CrossRefPubMedPubMedCentral
25.
go back to reference Mead N, Bower P. Patient-centred consultations and outcomes in primary care: a review of the literature. Patient Educ Couns. 2002;48:51–61.CrossRefPubMed Mead N, Bower P. Patient-centred consultations and outcomes in primary care: a review of the literature. Patient Educ Couns. 2002;48:51–61.CrossRefPubMed
26.
go back to reference Sale JE, Gignac MA, Hawker G, Beaton D, Frankel L, Bogoch E, et al. Patients do not have a consistent understanding of high risk for future fracture: a qualitative study of patients from a post-fracture secondary prevention program. Osteoporos Int. 2016;27:65–73.CrossRefPubMed Sale JE, Gignac MA, Hawker G, Beaton D, Frankel L, Bogoch E, et al. Patients do not have a consistent understanding of high risk for future fracture: a qualitative study of patients from a post-fracture secondary prevention program. Osteoporos Int. 2016;27:65–73.CrossRefPubMed
27.
go back to reference Hiligsmann M, Salas M, Hughes DA, Manias E, Gwadry-Sridhar FH, Linck P, et al. Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int. 2013;24:2907–18.CrossRefPubMed Hiligsmann M, Salas M, Hughes DA, Manias E, Gwadry-Sridhar FH, Linck P, et al. Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int. 2013;24:2907–18.CrossRefPubMed
Metadata
Title
Factors related to intentional non-initiation of bisphosphonate treatment in patients with a high fracture risk in primary care: a qualitative study
Authors
Karin M. A. Swart
Myrthe van Vilsteren
Wesley van Hout
Esther Draak
Babette C. van der Zwaard
Henriette E. van der Horst
Jacqueline G. Hugtenburg
Petra J. M. Elders
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Primary Care / Issue 1/2018
Electronic ISSN: 2731-4553
DOI
https://doi.org/10.1186/s12875-018-0828-0

Other articles of this Issue 1/2018

BMC Primary Care 1/2018 Go to the issue